Clcs.Pk

The company's capital structure is highly leveraged, with total liabilities of $18.82 million and total equity of -$18.54 million, resulting in a debt-to-equity ratio of -0.54. Liquidity is critically low, as evidenced by a current ratio of 0.02, indicating the company lacks sufficient current assets to cover its short-term obligations. Operating cash flow is negative at -$2.68 million, further highlighting the company's inability to generate cash from operations.

Profitability metrics are severely negative, with a net loss of $4.51 million and operating loss of $3.82 million. Return on equity is 24.34%, but this is misleading due to the negative equity base. Return on assets is -15.75%, indicating the company is not effectively utilizing its assets to generate profit. These metrics fall well below the industry median for biotechnology firms, which typically show positive returns and lower debt burdens.

The company's revenue concentration and geographic exposure are not disclosed in the available data, but the lack of segment reporting suggests a lack of diversification in its operations. This opacity increases the risk of overreliance on a single product line or market.

Growth trajectory is negative, with no disclosed revenue history or outlook for the current or next fiscal year. The absence of forward-looking guidance and the company's financial distress suggest a high likelihood of continued contraction in the near term.

Risk factors include severe liquidity constraints and a negative net cash position after subtracting total debt. Dilution risk is currently low, but the company's negative equity and high debt levels could necessitate equity financing in the future, which would increase dilution potential. No recent events, such as filings or transcripts, are available to provide additional context on the company's strategic direction.